CA2452677A1 - Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides - Google Patents
Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides Download PDFInfo
- Publication number
- CA2452677A1 CA2452677A1 CA002452677A CA2452677A CA2452677A1 CA 2452677 A1 CA2452677 A1 CA 2452677A1 CA 002452677 A CA002452677 A CA 002452677A CA 2452677 A CA2452677 A CA 2452677A CA 2452677 A1 CA2452677 A1 CA 2452677A1
- Authority
- CA
- Canada
- Prior art keywords
- factor
- factor vii
- related polypeptide
- vii
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101127 | 2001-07-20 | ||
| DKPA200101127 | 2001-07-20 | ||
| PCT/DK2002/000505 WO2003007983A1 (en) | 2001-07-20 | 2002-07-19 | Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2452677A1 true CA2452677A1 (en) | 2003-01-30 |
Family
ID=8160632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002452677A Abandoned CA2452677A1 (en) | 2001-07-20 | 2002-07-19 | Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1411973A1 (zh) |
| JP (1) | JP2004534855A (zh) |
| KR (1) | KR20040015821A (zh) |
| CN (1) | CN1304050C (zh) |
| AU (1) | AU2002354846B2 (zh) |
| BR (1) | BR0211256A (zh) |
| CA (1) | CA2452677A1 (zh) |
| CZ (1) | CZ200439A3 (zh) |
| HU (1) | HUP0400976A3 (zh) |
| IL (1) | IL159622A0 (zh) |
| MX (1) | MXPA04000415A (zh) |
| NO (1) | NO20040235L (zh) |
| PL (1) | PL369077A1 (zh) |
| RU (1) | RU2298416C2 (zh) |
| WO (1) | WO2003007983A1 (zh) |
| ZA (1) | ZA200400012B (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0302052A3 (en) | 1999-07-14 | 2005-12-28 | Novo Nordisk Healthcare Ag | Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis |
| CN101870729A (zh) | 2003-09-09 | 2010-10-27 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| TW200529870A (en) * | 2003-11-20 | 2005-09-16 | Novo Nordisk Healthcare Ag | Therapeutic use of factor XI |
| JP2007520530A (ja) * | 2004-02-05 | 2007-07-26 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 外傷の遅発型合併症の治療のための、ＶＩＩａ因子又はＶＩＩａ因子等価物の使用 |
| WO2006128497A1 (en) * | 2005-06-01 | 2006-12-07 | Novo Nordisk A/S | Pharmaceutical formulation of factor xi |
| DK2379096T3 (da) | 2008-12-19 | 2019-11-25 | Baxalta GmbH | TFPI-inhibitorer og fremgangsmåder til anvendelse |
| US8450275B2 (en) | 2010-03-19 | 2013-05-28 | Baxter International Inc. | TFPI inhibitors and methods of use |
| WO2012045569A1 (en) | 2010-10-06 | 2012-04-12 | Medimmune Limited | Factor ii and fibrinogen for treatment of haemostatic disorders |
| HUE046572T2 (hu) | 2012-03-21 | 2020-03-30 | Baxalta GmbH | TFPI inhibitorok és alkalmazási eljárások |
| CN105939607A (zh) * | 2014-01-31 | 2016-09-14 | 达纳-法伯癌症研究所股份有限公司 | 二氢蝶啶酮衍生物及其用途 |
| EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
| EP3380100A4 (en) | 2015-11-25 | 2019-10-02 | Dana-Farber Cancer Institute, Inc. | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF |
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59116213A (ja) * | 1982-12-24 | 1984-07-05 | Unitika Ltd | エアゾ−ル組成物 |
| JPH0780783B2 (ja) * | 1985-11-26 | 1995-08-30 | ノボ ノルディスク アクティーゼルスカブ | 出血障害の治療のための第▲ＶＩＩ▼ａ因子を含有する治療組成物 |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| FR2676231A1 (fr) * | 1991-05-07 | 1992-11-13 | Aetsrn | Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation. |
| AU2001287550B2 (en) * | 2000-09-13 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor VII variants |
-
2002
- 2002-07-19 JP JP2003513588A patent/JP2004534855A/ja active Pending
- 2002-07-19 PL PL02369077A patent/PL369077A1/xx not_active Application Discontinuation
- 2002-07-19 CA CA002452677A patent/CA2452677A1/en not_active Abandoned
- 2002-07-19 WO PCT/DK2002/000505 patent/WO2003007983A1/en not_active Application Discontinuation
- 2002-07-19 AU AU2002354846A patent/AU2002354846B2/en not_active Ceased
- 2002-07-19 CN CNB028185390A patent/CN1304050C/zh not_active Expired - Fee Related
- 2002-07-19 BR BR0211256-6A patent/BR0211256A/pt not_active IP Right Cessation
- 2002-07-19 CZ CZ200439A patent/CZ200439A3/cs unknown
- 2002-07-19 EP EP02750844A patent/EP1411973A1/en not_active Withdrawn
- 2002-07-19 RU RU2004105031/15A patent/RU2298416C2/ru not_active IP Right Cessation
- 2002-07-19 IL IL15962202A patent/IL159622A0/xx unknown
- 2002-07-19 KR KR10-2004-7000911A patent/KR20040015821A/ko not_active Application Discontinuation
- 2002-07-19 MX MXPA04000415A patent/MXPA04000415A/es unknown
- 2002-07-19 HU HU0400976A patent/HUP0400976A3/hu unknown
-
2004
- 2004-01-05 ZA ZA200400012A patent/ZA200400012B/en unknown
- 2004-01-19 NO NO20040235A patent/NO20040235L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1304050C (zh) | 2007-03-14 |
| JP2004534855A (ja) | 2004-11-18 |
| RU2298416C2 (ru) | 2007-05-10 |
| MXPA04000415A (es) | 2004-11-22 |
| RU2004105031A (ru) | 2005-04-20 |
| AU2002354846B2 (en) | 2007-08-02 |
| KR20040015821A (ko) | 2004-02-19 |
| CZ200439A3 (cs) | 2005-03-16 |
| CN1556710A (zh) | 2004-12-22 |
| PL369077A1 (en) | 2005-04-18 |
| EP1411973A1 (en) | 2004-04-28 |
| NO20040235L (no) | 2004-03-17 |
| BR0211256A (pt) | 2004-07-27 |
| ZA200400012B (en) | 2004-08-17 |
| HUP0400976A3 (en) | 2006-01-30 |
| WO2003007983A1 (en) | 2003-01-30 |
| IL159622A0 (en) | 2004-06-01 |
| HUP0400976A2 (hu) | 2004-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7125846B2 (en) | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides | |
| US20070027077A1 (en) | Pharmaceutical compositions comprising factor VII polypeptides and factor XI polypeptides | |
| US7078479B2 (en) | Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides | |
| US20080069810A1 (en) | Pharmaceutical Composition Comprising Factor VII Polypeptides and TAFI Polypeptides | |
| EP1446150A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors | |
| AU2002354846B2 (en) | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides | |
| US20030119743A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors | |
| US20060030531A1 (en) | Pharmaceutical composition comprising factor VII polypeptide and PAI-1 polypeptide | |
| AU2002354846A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides | |
| US20030119741A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides | |
| EP1446148A1 (en) | Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid | |
| US20080075709A1 (en) | Pharmaceutical Composition Comprising Factor VII Polypeptides And Thrombomodulin Polypeptides | |
| US20060025336A1 (en) | Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides | |
| AU2002340779B2 (en) | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides | |
| AU2002340779A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides | |
| EP1446155A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides | |
| AU2002340778B2 (en) | Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides | |
| EP1446145A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides | |
| AU2002340778A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides | |
| EP1446152A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors | |
| EP1446153A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and tissue plasminogen inhibitors | |
| EP1446154A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and alpha2 -antiplasmin polypeptides | |
| EP1446151A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and thrombomodulin polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |